New UK Government Promises Reform Of NICE - And Value-Added Pricing

NICE reforms are included in the legislative timetable of the new UK coalition government as the institute continues its work, recommending AstraZeneca's Iressa for lung cancer and rejecting Bayer's Nexavar for liver cancer.